Baidu
map

西媒盘点药物的意外疗效:PDE5抑制剂本该治心绞痛

2016-01-25 何冰 参考消息网

参考消息网1月25日报道西媒称,在大多数情况下,治愈或预防某种疾病都与某个药物或某项技术背后的数千小时研究工作息息相关,有时与医生的临床眼光有关,而与运气有关的几率却远超出我们的想象。   西班牙《趣味》月刊9月号发表题为《意外治愈》的文章称,药房里出售的很多药物原本是为了治疗某个疾病而研制出来的,却意外发现对其他疾病有疗效。这些惊喜是发生于观察患者身上的副作用或接受某种疾病治疗

参考消息网1月25日报道西媒称,在大多数情况下,治愈或预防某种疾病都与某个药物或某项技术背后的数千小时研究工作息息相关,有时与医生的临床眼光有关,而与运气有关的几率却远超出我们的想象。
西班牙《趣味》月刊9月号发表题为《意外治愈》的文章称,药房里出售的很多药物原本是为了治疗某个疾病而研制出来的,却意外发现对其他疾病有疗效。这些惊喜是发生于观察患者身上的副作用或接受某种疾病治疗的患者却发现其他疾病也痊愈时。上世纪五六十年代研制出的抗病毒药物金刚烷胺就是这种情况。加泰罗尼亚药理学研究所负责人、世界卫生组织顾问霍安·拉蒙·拉波尔特指出,发现金刚烷胺对流感效用不大,但帕金森氏病患者服用之后,震颤会减轻,就开始作为帕金森氏病的治疗药来研究。
治疗脱发的两个主要活性成分非那雄胺和米诺地尔,最初是分别用于治疗良性前列腺增生和高血压的。很多患者在服用之后出现了意想不到的后果:毛发会生长。虽然只长出一点儿,但也足以推动更多的试验,直到今天的广泛应用。类似的情况还有第一种用来治疗男性早泄的药物必利劲。西班牙性学协会主席米伦·拉腊萨瓦尔说:“它的研制是很偶然的。一些患者在服用含有其活性成分达泊西汀的抗抑郁药之后发现,这种药物有助于延迟射精。”
这一疗法在2009年被吹捧为“抗击早泄的万艾可”,结果发现并没有预想中那么有效,但其他一些偶然发现的药物和技术的应用的确堪称医学的里程碑,例如X射线。1895年11月8日,德国人威廉·伦琴在研究阴极射线时发现了X射线。这一消息迅速传开并引发激情。一些持怀疑态度的人认为,X射线将摧毁人类,而兴奋者则认为它具有让盲人重见光明的能力。一些人梦想着用X射线将图表直接送到学生的脑子里。毋庸置疑,很多人因为X射线而获益,但X射线也有它的阴暗面。1926年,美国生物学家赫尔曼·马勒指出,过度接受X射线照射可能会造成细胞的基因突变。
另一个科学上的巧合是宫颈癌诊断的有效检查方法的发现过程。巴伦西亚拉费医院妇科肿瘤学专家圣地亚哥·多明戈说:“阴道细胞学检查或称巴氏涂片是最便宜也拯救了最多女性生命的医学检查方法,让我们能够对宫颈癌进行预防和早期诊断。在它的使用普及之前,正常来讲我们发现的都是已经不可治愈的肿瘤。”
为之命名的医生乔治斯·帕帕尼古劳是在近百年前研究酒精对几内亚猪及其幼崽的影响时发现这种检查方法的。他的研究任务需要在排卵期前研究大量卵子,当时获取卵子的唯一方法就是牺牲掉很多雌性几内亚猪。为了避免这种情况,他决定利用几内亚猪定期阴道出血排出的卵子。如何做到呢?借助于一个小小的阴道涂片。在显微镜下观察样本时,他为所呈现的各种细胞形态而着迷,因此决定在人的身上进行同样的试验。他的妻子玛丽亚是历史上第一个接受阴道涂片检查的人。1924年,帕帕尼古劳对一名宫颈癌患者进行细胞学检查,发现了在之前的检查中都未能发现的新生肿瘤细胞,从而意外发现了非常有用的妇科筛查技术。
在这项发现之前一个世纪的19世纪20年代,已经确定了该如何更保险地实施剖宫产,但死亡率依然居高不下。首次实行这项外科手术的记录可追溯到1500年左右。在了解了这一病例的细节之后,现代妇科专家一致认为,那纯粹是靠运气。手术的实施者是一个名叫雅各布·尼费的瑞士屠夫。因为妻子难产,绝望的尼费获得当局的许可,采取了鲁莽的行动。他用平时工作用的一把刀子打开了妻子的腹部,取出了宝宝。母子俩都存活了下来,后来他们又生了5个孩子。专家认为,之所以一切顺利,是因为他的妻子碰巧出现异位妊娠,也就是说,胎儿是在子宫腔外发育的。如果是正常妊娠,母亲必会死于大出血,这次成功只是特殊情况。
1928年,英国科学家亚历山大·弗莱明在研究流感病毒时发现了青霉素。他在观察金黄色葡萄球菌的培养皿时发现,周围的霉菌使金黄色葡萄球菌停止生长。他推断,这种霉菌分泌出某种抑制生长的物质。他对霉菌进行了培养,发现它属于青霉属锈菌。但他的发现并没有引起多大关注,直至二战前夕,化学家厄恩斯特·鲍里斯·钱恩和沃尔特·弗洛里重新进行研究,并开启了青霉素的临床应用。当时人类已经进入抗生素时代,抗生素用以治疗结核病或梅毒等疾病,以及在战场上救治伤员。1945年与弗洛里和钱恩共同获得诺贝尔医学奖时,弗莱明谦逊地说:“我唯一的功绩是没有忽略那层锈菌的启示。有时人就是会发现自己并没有在寻找的东西。”
辉瑞公司在研究枸橼酸西地那非的效用时有了意外的发现。他们对用以治疗心绞痛,增加流向心脏的血液的活性成分的试验结果并不理想。但是在研究结束后,参与实验的人都不愿归还剩余的实验用药品。理由是在服用了这种药物之后,血液大量流向阴茎,引起阴茎的勃起。当时勃起功能障碍是常见病,而且没有治疗办法。他们细心选择这种口服药的形状、颜色和名称。药名应该短小、好记,具有积极意义。为此,科研人员将表示新药特性的“精力(vigor)”一词和使人联想到瀑布力量的“尼亚加拉(Niagara)”一词结合在一起。
一家大型营销公司在1998年推出了万艾可。用于临床试验和广告的成本是制药工业史上的最佳投资,因为它是迄今为止最赚钱的药品。
如果证实了西地那非的减肥功效,辉瑞制药的生意会做得更大。目前正在波恩大学药理和毒理学研究所开展这方面的研究。研究所负责人亚历山大·普法伊费尔两年前在提到在实验鼠身上进行的实验结果时表示,取得了“难以置信的效果”。使成百上千万男性重获性能力的这种药物能够“溶解腰部脂肪组织”。西地那非似乎能够抑制一种叫做环磷酸鸟苷的信使分子的分解,这种分子负责标记身体储存脂肪的方式:棕色脂肪更健康,白色脂肪更有害。科研团队还证实了这种信使分子能够控制血压,阻止促进发炎的激素的分泌。辉瑞公司是在仅对实验鼠用药一周并证实了药效之后公布成果的,并没有等待更长期的研究成果。
当局很清楚,鼓吹药物未经证实的疗效已经变成制药企业的一种商业手段,并对此类行为实行重罚。在美国司法部认定葛兰素史克公司对抗抑郁药物有欺诈性营销之后,该公司在2012年支付了23.8亿欧元罚款。
有些药物在特定用途下是无效的。以百忧解为例,它的确对严重抑郁有效,但对轻度抑郁无效。拉波尔特说:“如果一个人只是有些悲观,这药就没用。”但本不需要服用这种药物的患者掏钱消费才能保证丰厚的商业利润。
治疗精神病的药物氯丙嗪由法国化学家保罗·沙尔庞捷合成,外科医生亨利·拉博里率先使用。拉博里发现,除了具有麻醉效用以外,它还能消除患者的焦虑情绪。他在一篇研究报告中提到了这一点,心理学家皮埃尔·德尼凯和让·德莱看到了这篇论文,决定在重症患者身上试用,取得了相当好的结果,1954年获准使用。到上世纪60年代已经有5000多万人服用这种药物。
植入式心脏起搏器的发明者鲁内·埃尔姆奎斯特本来想要研究的并不是解决心率失常的机制,而是记录心脏声音的系统。听诊器的身世也很奇特。第一个听诊器的外观和现在截然不同,只是一个简单的纸筒。法国医生勒内·拉埃内克在1816年为了给一个年轻女子做检查而即兴制作了一个纸筒听诊器。他为什么不像平常所做的那样,将耳朵贴到患者的胸口呢?也许是这名患者太有魅力了,拉埃内克不敢使用这种方法,也不敢用手触碰。因此,他将一张报纸卷成筒,当听到放大了的心跳声时,他感到很惊讶。后来他用木管制作了一个喇叭形的听诊器,用于在胸部或背部进行检查。(编译/何冰)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1984869, encodeId=15f01984869b8, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Fri Mar 25 02:07:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851289, encodeId=31b718512895b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 29 00:07:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60779, encodeId=7c0260e7989, content=事实如此嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60781, encodeId=5b7760e8153, content=意外收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60597, encodeId=74836059e7a, content=意外哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60477, encodeId=a421604e721, content=这个是个意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Wed Jan 27 10:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60429, encodeId=4ab7604294e, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60077, encodeId=30f0600e749, content=奇特, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:36:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60076, encodeId=4c3e600e6b4, content=收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:35:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60041, encodeId=2a6460041d4, content=收获了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1984869, encodeId=15f01984869b8, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Fri Mar 25 02:07:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851289, encodeId=31b718512895b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 29 00:07:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60779, encodeId=7c0260e7989, content=事实如此嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60781, encodeId=5b7760e8153, content=意外收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60597, encodeId=74836059e7a, content=意外哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60477, encodeId=a421604e721, content=这个是个意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Wed Jan 27 10:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60429, encodeId=4ab7604294e, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60077, encodeId=30f0600e749, content=奇特, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:36:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60076, encodeId=4c3e600e6b4, content=收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:35:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60041, encodeId=2a6460041d4, content=收获了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-04-29 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1984869, encodeId=15f01984869b8, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Fri Mar 25 02:07:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851289, encodeId=31b718512895b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 29 00:07:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60779, encodeId=7c0260e7989, content=事实如此嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60781, encodeId=5b7760e8153, content=意外收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60597, encodeId=74836059e7a, content=意外哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60477, encodeId=a421604e721, content=这个是个意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Wed Jan 27 10:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60429, encodeId=4ab7604294e, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60077, encodeId=30f0600e749, content=奇特, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:36:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60076, encodeId=4c3e600e6b4, content=收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:35:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60041, encodeId=2a6460041d4, content=收获了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-27 李继凯

    事实如此嘛

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1984869, encodeId=15f01984869b8, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Fri Mar 25 02:07:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851289, encodeId=31b718512895b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 29 00:07:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60779, encodeId=7c0260e7989, content=事实如此嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60781, encodeId=5b7760e8153, content=意外收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60597, encodeId=74836059e7a, content=意外哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60477, encodeId=a421604e721, content=这个是个意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Wed Jan 27 10:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60429, encodeId=4ab7604294e, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60077, encodeId=30f0600e749, content=奇特, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:36:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60076, encodeId=4c3e600e6b4, content=收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:35:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60041, encodeId=2a6460041d4, content=收获了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-27 李继凯

    意外收获

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1984869, encodeId=15f01984869b8, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Fri Mar 25 02:07:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851289, encodeId=31b718512895b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 29 00:07:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60779, encodeId=7c0260e7989, content=事实如此嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60781, encodeId=5b7760e8153, content=意外收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60597, encodeId=74836059e7a, content=意外哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60477, encodeId=a421604e721, content=这个是个意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Wed Jan 27 10:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60429, encodeId=4ab7604294e, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60077, encodeId=30f0600e749, content=奇特, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:36:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60076, encodeId=4c3e600e6b4, content=收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:35:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60041, encodeId=2a6460041d4, content=收获了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-27 文医生

    意外哦

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1984869, encodeId=15f01984869b8, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Fri Mar 25 02:07:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851289, encodeId=31b718512895b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 29 00:07:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60779, encodeId=7c0260e7989, content=事实如此嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60781, encodeId=5b7760e8153, content=意外收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60597, encodeId=74836059e7a, content=意外哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60477, encodeId=a421604e721, content=这个是个意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Wed Jan 27 10:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60429, encodeId=4ab7604294e, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60077, encodeId=30f0600e749, content=奇特, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:36:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60076, encodeId=4c3e600e6b4, content=收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:35:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60041, encodeId=2a6460041d4, content=收获了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-27 vinson820801

    这个是个意外发现

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1984869, encodeId=15f01984869b8, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Fri Mar 25 02:07:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851289, encodeId=31b718512895b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 29 00:07:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60779, encodeId=7c0260e7989, content=事实如此嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60781, encodeId=5b7760e8153, content=意外收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60597, encodeId=74836059e7a, content=意外哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60477, encodeId=a421604e721, content=这个是个意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Wed Jan 27 10:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60429, encodeId=4ab7604294e, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60077, encodeId=30f0600e749, content=奇特, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:36:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60076, encodeId=4c3e600e6b4, content=收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:35:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60041, encodeId=2a6460041d4, content=收获了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-27 mingliqinmian

    我仔细看看

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1984869, encodeId=15f01984869b8, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Fri Mar 25 02:07:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851289, encodeId=31b718512895b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 29 00:07:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60779, encodeId=7c0260e7989, content=事实如此嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60781, encodeId=5b7760e8153, content=意外收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60597, encodeId=74836059e7a, content=意外哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60477, encodeId=a421604e721, content=这个是个意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Wed Jan 27 10:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60429, encodeId=4ab7604294e, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60077, encodeId=30f0600e749, content=奇特, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:36:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60076, encodeId=4c3e600e6b4, content=收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:35:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60041, encodeId=2a6460041d4, content=收获了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-26 xyfg98

    奇特

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1984869, encodeId=15f01984869b8, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Fri Mar 25 02:07:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851289, encodeId=31b718512895b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 29 00:07:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60779, encodeId=7c0260e7989, content=事实如此嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60781, encodeId=5b7760e8153, content=意外收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60597, encodeId=74836059e7a, content=意外哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60477, encodeId=a421604e721, content=这个是个意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Wed Jan 27 10:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60429, encodeId=4ab7604294e, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60077, encodeId=30f0600e749, content=奇特, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:36:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60076, encodeId=4c3e600e6b4, content=收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:35:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60041, encodeId=2a6460041d4, content=收获了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-26 xyfg98

    收获

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1984869, encodeId=15f01984869b8, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Fri Mar 25 02:07:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851289, encodeId=31b718512895b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 29 00:07:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60779, encodeId=7c0260e7989, content=事实如此嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60781, encodeId=5b7760e8153, content=意外收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:53:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60597, encodeId=74836059e7a, content=意外哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60477, encodeId=a421604e721, content=这个是个意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Wed Jan 27 10:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60429, encodeId=4ab7604294e, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60077, encodeId=30f0600e749, content=奇特, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:36:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60076, encodeId=4c3e600e6b4, content=收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 26 21:35:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60041, encodeId=2a6460041d4, content=收获了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-26 收获你的美

    收获了

    0

相关资讯

“女用PDE5抑制剂”英国上市 其疗效被怀疑

一种标榜为“女性伟哥”的草本药物本月在英国连锁药店上市,声称可以显著改善女性性机能障碍。不过,一些研究人员怀疑这种药物的确实疗效。 天然草本 英国《每日邮报》网站8日报道,这种药物叫“女性碧萝芷”,本月进驻英国“霍伦德和巴雷特”药房。 这种药物一瓶60粒,售价37.95英镑(约合62.3美元),用法每日两粒。报道说,这种药物据称可以给女性带来更“欢愉”体验。 生产商法尔诺德制药公司介绍

“女性PDE5抑制剂”有望上市 专家警告或被用于约会强奸

美国联邦卫生顾问委员会4日以18:6的投票数,认定一款“女性伟哥”的治疗功效远大于可能带来的意外伤害风险,推荐美国食品和药物管理局(FDA)批准这种药物,它有望成为第一种用于促进女性性欲的上市药。 这款粉红色的小药片,名为氟立班丝氨(flibanserin),用于治疗停经前妇女非疾病原因的性功能障碍,是一种实验性药物。 氟立班丝氨直接作用于女性大脑控制性愉悦区,从而恢复女性逐渐衰退的性欲。

JAMA:PDE5抑制剂可能增加了恶性黑色素瘤的风险

    背景  对于口服勃起功能障碍药物的靶点,5型磷酸二酯酶(PDE5)抑制剂,是与恶性黑色素瘤的发展途径密切相关的一部分。最近报道西地那非使用者的恶性黑色素瘤的风险增加。    意义  为了检测使用PDE5抑制剂和黑素瘤风险之间的联系,包括特定PDE5抑制剂的数据,处方编号,和黑素瘤的阶段。    方法  

OM:辉瑞万艾可增加男子皮肤癌风险

根据2014年4月9日英国《每日邮报》的相关报道,研究发现辉瑞公司生产的万艾可(促进男性勃起的药物)可增加男性患有黑色素瘤的风险,其风险高达84%。 美国的研究发现,那些服用昔多芬(商品名:万艾可)药物的人比起未服用的人,具有高达84%比例的黑色素瘤风险,该病恶化后可导致患者死亡。 人们认为,壮阳药物可能具有相同的基因机制来激活皮肤癌发病。 研究者同时表示,本研究结果

BMC Med:PDE5抑制剂新用途,为你提供“贴心保护”

 BMC医学 10月19日公布了一项最新研究成果,研究发现,万艾可(伟哥)也许能够安全用于治疗心脏病。该研究表明,在不同心脏病病程中,长期每日服用伟哥都能起到保护心脏的作用,而且几乎没有副作用。[pdf free]万艾可的主要成分是磷酸二酯酶5抑制剂(phosphodiesterase-5 inhibitor,PDE5i),同时也是其他治疗勃起障碍常用药的主要成分。磷酸二酯酶5的作用是防

Baidu
map
Baidu
map
Baidu
map